OBJECTIVES: Age-related macular degeneration (AMD) is the leading cause of blindness and visual impairment. The prevalence increases proportionally to the number of aging population. Little is known about its economic consequences, therefore; this study is undertaken to determine economic outcomes associated with AMD in Thailand from the societal perspective. METHODS: Health resource utilization and direct medical costs were estimated based on a retrospective medical chart review of AMD patients at a University hospital during 2008-2009. We collected outpatient drug, intervention, medical visit and laboratory costs. Charges were converted to costs using a cost-to-charge ratio. Direct non-medical costs and indirect costs were obtained from patient’s interview using a structured questionnaire at a University-affiliated hospital. Patients were inquired about costs of transportation, additional food, medical device, house modification, and opportunity costs of care giver. Descriptive statistics were used. All costs were adjusted to year 2009 values.RESULTS: Twenty-two patient’s medical records were reviewed. Mean age was 67 years with 64% of male. The average number of medical visits was 11, while the cost for each outpatient visit was 233 USD. Drug costs accounted for 79% of total direct medical costs. The annual mean direct medical costs of AMD were USD2963.  For direct non-medical and indirect costs, 31 patients were included. Mean age was 62 years with 39% of male. Four patients (12.9%) bought extra medical devices. A quarter of them (26%) needed a care giver to take care at home. On average, the amount of time care givers spent for caring patients was 11.3 hours/month. The mean annual direct non-medical cost was USD168 and USD85 for the opportunity costs of care giver. CONCLUSIONS: The economic consequences AMD were substantial. These estimates can be used as input parameters in a study evaluating the cost-effectiveness of interventions in patients with AMD.